person · Reporting owner

Barbarosh Craig A.

Disclosed activity across 7 companies

Tapewire entity: 911
SEC CIK: 0001472457

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Bazaarvoice IncBV · Entity 169747	Director	February 01, 2018	February 05, 2018
Evolent Health, Inc.EVH · Entity 5492	Director	June 04, 2026	June 08, 2026
LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447	Director	July 08, 2024	July 10, 2024
ModivCare IncMODV · Entity 76927	Director	December 23, 2024	January 03, 2025
NEXTGEN HEALTHCARE, INC.NXGN · Entity 108396	Director	November 09, 2023	November 13, 2023
Sabra Health Care REIT, Inc.SBRA · Entity 886	Director	August 31, 2026	September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Bazaarvoice Inc

Report date February 01, 2018 · Filed February 05, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2018-02-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2018-02-01 · Disposition to issuer · Disposed 1,720 · Balance 18,920 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among BV Parent, LLC, BV Merger Sub, Inc. and Bazaarvoice, Inc. (the "Issuer"), dated November 26, 2017 (as amended, the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $5.50 per share. Row 2 · 2018-02-01 · Disposition to issuer · Disposed 18,920 · Balance 0 F2: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock were cancelled in exchange for cash payments in the amount of $5.50 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among BV Parent, LLC, BV Merger Sub, Inc. and Bazaarvoice, Inc. (the "Issuer"), dated November 26, 2017 (as amended, the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $5.50 per share.

F2: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock were cancelled in exchange for cash payments in the amount of $5.50 per share.

Evolent Health, Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	95,031	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 41,096 · Balance 95,031 F1: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted to Mr. Barbarosh pursuant to the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.

F2: Securities vest on the earlier of June 4, 2027, and the date of the Company's 2027 annual meeting, subject to the reporting person's continued service on the vesting date.

LIFECORE BIOMEDICAL, INC. \DE\

Report date July 08, 2024 · Filed July 10, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectIn Trust	88,073	Reported balance After 2024-07-08 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2024-07-08 · Grant · Acquired 30,000 · Balance 88,073 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

F2: Vests on earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

ModivCare Inc

Report date December 23, 2024 · Filed January 03, 2025

This filing explicitly reported no securities owned.

NEXTGEN HEALTHCARE, INC.

Report date November 09, 2023 · Filed November 13, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	0	Reported balance After 2023-11-09 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2023-11-09 · Disposition to issuer · Disposed 67,269 · Balance 0 F1: Includes 10,086 outstanding vested shares of restricted stock. F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F4: The ownership form includes both direct and indirect holdings. F5: Indirect ownership includes the holdings of the The Barbarosh Family Trust established May 29, 2007.
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-09 · Disposition to issuer · Disposed 9,483 · Balance 0 F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level. F6: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 10,086 outstanding vested shares of restricted stock.

F2: Pursuant to the Agreement and Plan of Merger, dated September 5, 2023, by and among the Issuer, Next Holdco Co., LLC ("Next Holdco") and Next Merger Sub, Inc. ("Merger Sub"), the Issuer became a wholly owned subsidiary of Next Holdco upon consummation of the merger with Merger Sub on November 9, 2023 (the "Effective Time"). At the Effective Time: (a) each of the Issuer's outstanding shares of common stock, each outstanding restricted stock unit and each outstanding deferred stock unit was cancelled and automatically converted into the right to receive $23.95 in cash; (b) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was cancelled and converted into the right to receive $23.95 in cash less the applicable per share exercise price; and (c) each of the Issuer's outstanding performance stock units was cancelled and converted into the right to receive $23.95 (with respect to the Issuer shares underlying the portion of such award which had

F3: (Continued from footnote 2) vested), and, with respect to any portion of such award the vesting of which remained subject to achievement of performance objectives as of October 4, 2023, $23.95 for each Issuer share underlying the portion of the award that would vest as a result of the Merger in accordance with the terms and conditions of the applicable award agreement, which for the units granted in 2020 assumed performance achievement at the "maximum" level; for the units granted in 2021, assumed performance achievement above "target" with partial achievement of the next stock price hurdle; and for the units granted in 2022, assumed performance achievement at 140% of the "target" level.

F4: The ownership form includes both direct and indirect holdings.

F5: Indirect ownership includes the holdings of the The Barbarosh Family Trust established May 29, 2007.

F6: The Deferred Stock Units credited under the Deferred Compensation Plan are generally payable in the form elected or provided under the Deferred Compensation Plan on the earlier of (i) the date or event elected by the reporting person, (ii) within 90 days following the participant's separation from service as defined under the Deferred Compensation Plan, or (ii) upon death, disability or change in control as defined under the Deferred Compensation Plan.

Sabra Health Care REIT, Inc.

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	54,580	Reported balance After 2026-08-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-31 · Grant · Acquired 791 · Balance 54,580 F1: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2: Consists of 7,027 unvested stock units and 47,553 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.
Common StockSEC Table I · non-derivative	IndirectBy The Barbarosh Family Trust	104,453	Reported balance Holding disclosure · report date 2026-08-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 104,453

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate.

F2: Consists of 7,027 unvested stock units and 47,553 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARATANA THERAPEUTICS, INC.

Report date July 18, 2019 · Filed July 18, 2019

Section 16 reporting ended · disclosed 2019-07-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-07-18 transaction · row 1 1 source row Row 1 · 2019-07-18 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2) F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.34	Direct	Reported balance After 2019-07-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-07-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80	Direct	Reported balance After 2019-07-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-07-18 · Disposition to issuer · Disposed 7,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On July 18, 2019, pursuant to that certain Agreement and Plan of Merger dated April 26, 2019 (the "Merger Agreement") among Aratana Therapeutics, Inc. (the "Company"), Elanco Animal Health Incorporated ("Elanco") and Elanco Athens, Inc., a Delaware corporation and a direct wholly owned subsidiary of Elanco ("Elanco Athens"), Elanco Athens merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Elanco. Pursuant to the Merger Agreement, each outstanding share of Company common stock (other than certain excluded shares as described in the Merger Agreement) was converted into the right to receive (A) 0.1481 validly issued, fully paid and non-assessable shares of Elanco common stock (the "Stock Consideration"), having a market value of $4.91 on the effective date of the Merger, (B) one contingent value right, which represents the contractual right to receive a contingent cash (continued in footnote 2)

F2: (continued from footnote 1) payment of $0.25 per share of Company common stock if a specified milestone is achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated July 18, 2019, by and among Elanco, Broadridge Corporate Issuer Solutions, Inc., and UMB Bank, National Association (together with the Stock Consideration, the "Merger Consideration").

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of all outstanding unvested Company restricted stock awards was accelerated in full and each such restricted stock award was cancelled and terminated as of the effective time of the Merger. Each holder of a Company restricted stock award received the right to the Merger Consideration due with respect to the shares of Company common stock received in exchange for such accelerated restricted stock awards.

F4: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, the vesting of each outstanding Company option was accelerated in full and each such option was net exercised and immediately cancelled and terminated. Each holder of such a Company option was treated as holding the number of shares of Company common stock issuable upon exercise of the option in full multiplied by the Net Exercise Ratio (as defined in the Merger Agreement), and received the right to the Merger Consideration with respect to such shares.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 28, 2018 Filed Mar 2, 2018 16:38 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	121	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000028 · wf-form4_152000866759383.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,926 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 1,551 unvested stock units and 17,223 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 01, 2018 Filed Feb 5, 2018 12:01 UTC	Bazaarvoice Inc BV · Entity 169747	Disposition to issuerCommon Stock	18,920	$5.50	$104,060.00	Disclosure SEC source: 0001209191-18-007314 · doc4.xml · nonDerivative · entry 2 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock were cancelled in exchange for cash payments in the amount of $5.50 per share. Read SEC document
February 01, 2018 Filed Feb 5, 2018 12:01 UTC	Bazaarvoice Inc BV · Entity 169747	Disposition to issuerCommon Stock	1,720	$5.50	$9,460.00	Disclosure SEC source: 0001209191-18-007314 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,920 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, by and among BV Parent, LLC, BV Merger Sub, Inc. and Bazaarvoice, Inc. (the "Issuer"), dated November 26, 2017 (as amended, the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $5.50 per share. Read SEC document
December 29, 2017 Filed Jan 4, 2018 01:28 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	1,065	$0.00	$0.00	Disclosure SEC source: 0001510192-18-000009 · wf-form4_151502927905889.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,805 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or December 29, 2022. F2 · balance_after: Includes 2,266 unvested stock units and 16,387 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 30, 2017 Filed Dec 4, 2017 20:34 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	119	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000121 · wf-form4_151241962915268.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,740 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 2,644 unvested stock units and 15,532 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
September 29, 2017 Filed Oct 3, 2017 20:09 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	911	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000106 · wf-form4_150706133975982.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,621 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or September 29, 2022. F2 · balance_after: Includes 3,311 unvested stock units and 14,877 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
September 28, 2017 Filed Oct 2, 2017 16:17 UTC	Bazaarvoice Inc BV · Entity 169747	GrantCommon Stock	20,640	$0.00	$0.00	Disclosure SEC source: 0001209191-17-054603 · doc4.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,640 F1 · shares: One-twelfth (1/12) of the shares vest on December 28, 2017, and an additional one-twelfth (1/12) of the shares vest on the corresponding day of each three month period thereafter, subject to this director's continued service as a director of the company through each such date. Read SEC document
August 22, 2017 Filed Aug 23, 2017 20:37 UTC	NEXTGEN HEALTHCARE, INC. QSII · Entity 108396	GrantCommon Stock	11,724	$0.00	$0.00	Disclosure SEC source: 0000708818-17-000036 · wf-form4_150353504835150.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 62,593 F1 · ownership.nature: The Barbarosh Family Trust established May 29, 2007. Read SEC document
August 18, 2017 Filed Aug 22, 2017 21:21 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	326	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000100 · wf-form4_150343686741207.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,710 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 4,049 unvested stock units and 28,623 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 30, 2017 Filed Jul 5, 2017 21:52 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	829	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000073 · wf-form4_149929150567528.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,384 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or June 30, 2022. F2 · balance_after: Represents 4,342 unvested stock units and 27,175 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
June 20, 2017 Filed Jun 21, 2017 16:28 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	4,342	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000067 · wf-form4_149806250264692.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,555 F1 · shares: Grant of restricted stock units under the Issuer's 2009 Performance Incentive Plan. The units vest in equal monthly installments beginning July 20, 2017 and ending on the earlier of June 19, 2018 or the day before the date of the next annual stockholders' meeting. F2 · balance_after: Includes 4,342 unvested stock units and 31,257 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
May 31, 2017 Filed Jun 2, 2017 22:11 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	318	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000051 · wf-form4_149644148519064.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,213 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 435 unvested stock units and 30,822 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
March 31, 2017 Filed Apr 4, 2017 17:55 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	716	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000033 · wf-form4_149132851239693.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,895 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or March 31, 2022. F2 · balance_after: Represents 1,285 unvested stock units and 29,654 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 28, 2017 Filed Mar 2, 2017 23:00 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	263	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000021 · wf-form4_148849559218346.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,179 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 1,714 unvested stock units and 29,307 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
December 31, 2016 Filed Jan 5, 2017 01:08 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	716	$0.00	$0.00	Disclosure SEC source: 0001510192-17-000009 · wf-form4_148357851085908.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,916 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or December 31, 2021. F2 · balance_after: Includes 2,536 unvested stock units and 28,222 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
November 30, 2016 Filed Dec 3, 2016 02:29 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	319	$0.00	$0.00	Disclosure SEC source: 0001510192-16-000153 · primary_doc.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,200 F1 · shares: Represents stock units credited to the reporting person in the form of dividend equivalent payments on stock units previously granted to the reporting person that are outstanding under the Issuer's 2009 Performance Incentive Plan, calculated on the basis of the market value of the Issuer's common stock on the dividend payment date. These units will vest and become payable on the same terms as the original stock units to which they relate. F2 · balance_after: Includes 2,959 unvested stock units and 27,904 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document
September 30, 2016 Filed Oct 4, 2016 00:47 UTC	Sabra Health Care REIT, Inc. SBRA · Entity 886	GrantCommon Stock	695	$0.00	$0.00	Disclosure SEC source: 0001510192-16-000143 · primary_doc.xml · nonDerivative · entry 1 Barbarosh Craig A. · CIK 0001472457 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,881 F1 · shares: Represents stock units received by the reporting person in lieu of quarterly director fees pursuant to an election under the Issuer's Non-Employee Directors Stock-For-Fees Program. The units are fully vested and are payable in an equivalent number of shares of the Issuer's Common Stock on or within sixty (60) days following the earlier of the reporting person's separation from service or September 30, 2021. F2 · balance_after: Includes 3,735 unvested stock units and 27,073 stock units that have vested but the payment of which has been deferred. Each stock unit represents the right to receive one share of the Issuer's Common Stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.